Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 331-341

  Pal, Ajai ^a   Khan, Sumsullah ^a   Wang, Yue Fen ^a   Kamath, Narayan ^a   Sarkar, Asis K ^a   Ahmad, Ateeq ^a   Sheikh, Saifuddin ^a   Ali, Shahid ^a   Carbonaro, Danielle ^a   Zhang, Allen ^a   Ahmad, Imran ^a  

^a NeoPharm Inc   (United States)

Author keywords

Camptothecin; CPT 11; Drug delivery; Liposome; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLYCOPROTEIN P; HEMOGLOBIN; IRINOTECAN; LIPOSOME;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DOG; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LEUKEMIA; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA P388; LIPOSOMES; MALE; MICE; MICE, SCID; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20144388242     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hsiang YH, Hertzberg R, Hecht S and Liu FJ: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
2. Hsiang YH and Liu F: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726, 1988.
3. Stewart AF, Herrera RE and Nordheim A: Rapid induction of c-fos transcription reveals quantitative linkage of RNA polymerase II and DNA topoisomerase I enzyme activities. Cell 60: 141-149, 1990.
4. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T and Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in patients with metastatic colorectal cancer. J Clin Oncol 10: 909-913, 1993.
5. Cardenal F, Domine M, Massuti B, Carrato A, Felip E, Garrido P, Juan O, Artal A, Barneto I, Lopez-Vivanco G, Balcells M and Rosell R: Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Lung Cancer 39: 201-207, 2003.
6. Kollmannsberger C, Mross K, Jakob A, Kanz L and Bokemeyer C: Topotecan: A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56: 1-12, 1999.
7. Humerickhouse R, Lohrbach K, Li L, Bosron WF and Dolan M E: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60: 1189-1192, 2000.
8. Kaneda N, Ngata H, Futura T and Yokokura T: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715-1720, 1990.
9. Takimoto CH and Arbuck SG: Topoisomerase I targeting agents: the campothecins. In: Chabner BA, Lango DL (Eds), Cancer Chemotherapy and Biotherapy: Principal and Practice,3rd ed. Lippincot Williams & Wilkins, Philadelphia, 579-646, 2001.
10. Langer R: Drug delivery and targeting. Nature 392: 5-10, 1998.
11. Gokhle PC, Pei J, Zhang C, Ahmad I, Rahman A and Kasid U: Improved safety, pharmacokinetics and therapeutic efficacy profiles of novel liposomal formulation of mitoxantrone. Anticancer Res 21: 3313-3321, 2001.
12. Gabizon A and Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors: Proc Natl Acd Sci USA 85: 6949-6953, 1988.
13. Burke TG and Gao X: Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J Pharma Sci 83: 967-969, 1994.
14. Sadzuka Y, Hirotsu S and Hirota S: Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 127: 99-106, 1998.
15. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S and Ahmad I: Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharma 270: 93-107, 2004.
16. Institute of Animal Laboratory Resources. Guide for Care and Use of Laboratory Animals. Commission on Life Sciences, National Research Council; National Academy Press; Washington D.C. 1996.
17. Guo W, Ahmad A, Khan S, Dahhani F, Wang YF and Ahmad I: Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy- camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38). J Chromatography B 791: 85-92, 2003.
18. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP and Jain RK: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55: 3752-3756, 1995.
19. Kawato Y, Sekiguchi M, Akahane K, Tsutomi Y, Hirota Y, Kuga H, Suzuki W, Hakusui H and Sato K: Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J Pharm Pharmacol 45: 444-448, 1993.
20. Morton CL, Wadkins RM, Danks MK and Potter PM: The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 59: 1458-1463, 1999.
21. Bleiberg H and Cvitkovic E: Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer 3: S18-23, 1996.
22. Sadzuka Y: Effective prodrug liposome and conversion to active metabolite. Curr Drug Metab 1: 31-48, 2002.
23. Tardi P, Choice E, Masin D, Redelmeier T, Bally M and Madden TD: Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60: 3389-3393, 2000.
24. Burke TG, Mishra AK, Wani MC and Wall ME: Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry, 32: 5352-5364, 1993.
25. Davies B, and Morris T: Physiological parameters in laboratory animals and humans. Pharmaceutical Res 10: 1093-1095, 1993.
26. Singer JW, De Vries P, Bhatt R, Tulinsky J, Klein P, Li C, Milas L, Lewis RA and Wallace S: Conjugation of camptothecins to poly-(L-glutamic acid). Ann NY Acad Sci 922: 136-150, 2000.